B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data |
| |
Authors: | Khattri Saakshi Zandman-Goddard Gisele Peeva Elena |
| |
Affiliation: | Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. skhattri@montefiore.org |
| |
Abstract: | The increased awareness of the role of humoral immunophysiology in antiphospholipid syndrome (APS) has aroused interest in B cells as therapeutic targets in this disease. This paper reviews the literature on B cell directed therapies in human and experimental APS. The clinical data is limited to B cell depletion with rituximab and comprises case reports and case series. Murine studies include use of modulators of B cell function such as belimumab and abatacept. In both human and murine studies, B cell directed therapies appeared to have clinical and serologic beneficial effects including a decrease in the antiphospholipid antibody titers after treatment. Randomized controlled clinical trials are needed to determine whether B cell depletors and/or B cell modulators can be effective agents for treating patients with APS. |
| |
Keywords: | Antiphospholipid syndrome (APS) Antiphospholipid antibodies (aPL) Anticardiolipin antibody (aCL) Beta 2 Glycoprotein I antibody (β2GPI) Lupus anticoagulant (LAC) Rituximab Catastrophic antiphospholipid syndrome (CAPS) |
本文献已被 ScienceDirect PubMed 等数据库收录! |